Palbociclib API
| Name of Product | Palbociclib |
|---|---|
| CAS No | 571190‑30‑2 |
| Therapeutic use:- | CDK4/6 inhibitor – HR+, HER2– breast cancer |
| Grade | IH |
| Form:- | API Powder |
| Status | Commercial |
Product Overview
Palbociclib (571190-30-2) is an active ingredient that is used to prepare the medication used in the treatment of breast cancer. It belongs to a class of drugs called CDK4/6 inhibitors. Such drugs block the enzymes controlling cell division, and therefore, cancer cells cannot develop. Once the enzymes are inactivated, cancer cells stop dividing and begin dying. Palbociclib has become one of the most important targeted agents in cancer therapy owing to its ability to slow down tumor growth and be used with hormone-based treatments.
Therapeutic Applications
Palbociclib (571190-30-2) is used for the treatment of hormone receptor-positive, HER2-negative breast cancer. They are the most common forms of adult breast cancer. Palbociclib is taken by mouth and usually with medication like letrozole or fulvestrant. Palbociclib is not like traditional chemotherapy. It targets only cancer-directed enzymes, not normal cells. That means fewer side effects and faster recovery periods between drug cycles.
For metastatic or advanced breast cancer:
Specification Parameters
Each batch meets cGMP and ICH Q7 guidelines. Full analytical data, including HPLC, NMR, and MS results, are supplied to confirm structure and purity.
Packaging & Storage
Palbociclib (571190-30-2) is adequately packaged to protect it from air, light, and moisture.
Why Choose Actiza Pharma
Actiza Pharma is a trusted company that makes and exports oncology APIs like Palbociclib.Â